New prostate cancer drug shows promise in early trial

NCT ID NCT04662580

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-stage trial tests a new drug called ARX517, which is designed to find and kill prostate cancer cells while sparing healthy ones. It is being tested alone or with other standard treatments in 183 men with prostate cancer that has spread to other parts of the body. The main goal is to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARX517 (a drug that targets prostate cancer cells and delivers a toxin to kill them)
What this could lead to: If it works, this could point toward a new treatment option for men with advanced prostate cancer that has spread.
What could go wrong: This is an early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work well or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States
GU Research Network

Omaha, Nebraska, 68130, United States
Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202-5116, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UCSF Medical Center at Mission Bay

San Francisco, California, 94143-2350, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of California, Los Angeles School of Medicine

Los Angeles, California, 90095-3000, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109-5000, United States
University of Washington

Seattle, Washington, 98101, United States
Washington University St. Louis School Medicine Siteman Cancer Center

St Louis, Missouri, 63110, United States
Weill Cornell Medical College

New York, New York, 10021-5663, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.